Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

PaperCitations, authors & open-access status

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 392 citations, 2023 year and closed oa status.

392
Citations
2023
Year
closed
OA Status

Related on ScholarIQ

Julio Rosenstock
Author
Axel Haupt
Author
The Lancet
Journal
Diabetes Treatment and Management
Topic
Diabetes Treatment and Management
Topic
Bariatric Surgery and Outcomes
Topic
470M+ articles · free account